|
The Start of the First-Ever ADNP Clinical Trial Marks Historic Moment in ADNP Research History!
|
Researchers at the Gozes Lab have identified a potential drug treatment for children with ADNP, called CP201/NAP. For the first time, we have in front of us a possible treatment for children with ADNP Syndrome. 2017 marks the initiation of the collaboration between ADNP-KRF and Coronis Neuroscienes to begin moving forward with clinical trials of CP201/NAP for ADNP Syndrome.
RECRUITMENT FOR THIS TRIAL HAS NOT YET BEGUN
RECRUITMENT FOR THIS TRIAL HAS NOT YET BEGUN
“It usually takes decades for a rare disease to go from discovery to clinical trial. We have shot this projection out of the water in just 2 short years, a phenomenal testament to the hard work of Dr. Illana Gozes from the Gozes Lab in Tel Aviv Israel.”
Sandra Bedrosian Sermone, Founder & President of the ADNP Kids Research Foundation
Coronis NeuroSciences is a specialty pharma company focused on the development of Innovative therapies for Neurocognitive and Neurodegenerative disorders.
Coronis’ pipeline currently includes an innovative drug for major for ADNP Syndrome and is in the pre-clinical stage. CP201 is the Coronis' leading drug and is developed to treat ADNP-Related Syndrome.
Coronis’ pipeline currently includes an innovative drug for major for ADNP Syndrome and is in the pre-clinical stage. CP201 is the Coronis' leading drug and is developed to treat ADNP-Related Syndrome.
